MA27535A1 - Compositions et procedes permettant d'ameliorer l'administration aux muqueuses de peptides de liaison du recepteur y2, et procedes pour le traitement et la prevention de l'obesite - Google Patents

Compositions et procedes permettant d'ameliorer l'administration aux muqueuses de peptides de liaison du recepteur y2, et procedes pour le traitement et la prevention de l'obesite

Info

Publication number
MA27535A1
MA27535A1 MA28337A MA28337A MA27535A1 MA 27535 A1 MA27535 A1 MA 27535A1 MA 28337 A MA28337 A MA 28337A MA 28337 A MA28337 A MA 28337A MA 27535 A1 MA27535 A1 MA 27535A1
Authority
MA
Morocco
Prior art keywords
methods
obesity
prevention
compositions
treatment
Prior art date
Application number
MA28337A
Other languages
English (en)
Inventor
C Quay Steven
Brandt Gordon
S Kleppe Mary
J Macevilly Conor
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/322,266 external-priority patent/US7166575B2/en
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of MA27535A1 publication Critical patent/MA27535A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
MA28337A 2002-12-17 2005-06-15 Compositions et procedes permettant d'ameliorer l'administration aux muqueuses de peptides de liaison du recepteur y2, et procedes pour le traitement et la prevention de l'obesite MA27535A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/322,266 US7166575B2 (en) 2002-12-17 2002-12-17 Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US49322603P 2003-08-07 2003-08-07
US50117003P 2003-09-08 2003-09-08
US51078503P 2003-10-10 2003-10-10
US51729003P 2003-11-04 2003-11-04
US51881203P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
MA27535A1 true MA27535A1 (fr) 2005-09-01

Family

ID=32686401

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28337A MA27535A1 (fr) 2002-12-17 2005-06-15 Compositions et procedes permettant d'ameliorer l'administration aux muqueuses de peptides de liaison du recepteur y2, et procedes pour le traitement et la prevention de l'obesite

Country Status (13)

Country Link
US (4) US7186691B2 (fr)
EP (1) EP1581245A2 (fr)
JP (1) JP2006516262A (fr)
AU (1) AU2003299722A1 (fr)
BR (1) BR0316685A (fr)
CA (1) CA2510199A1 (fr)
CO (1) CO5700705A2 (fr)
EA (1) EA008829B1 (fr)
EC (1) ECSP055839A (fr)
MA (1) MA27535A1 (fr)
MX (1) MXPA05006572A (fr)
NO (1) NO20053430L (fr)
WO (1) WO2004056314A2 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP2280021B1 (fr) 1999-06-29 2016-02-17 MannKind Corporation Formulations pharmaceutiques comprenant d'insulin complexe avec une dicetopiperazine
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
WO2004066966A2 (fr) * 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues du peptide yy
US8957034B2 (en) * 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
WO2005078454A2 (fr) * 2004-02-09 2005-08-25 Nastech Pharmaceutical Company Inc. Procedes permettant de mesurer la quantite de peptide yy dans le sang
PT2319500E (pt) * 2004-03-12 2013-01-23 Biodel Inc Composições de distribuição de fármacos de actuação rápida
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
JP2007529463A (ja) * 2004-03-17 2007-10-25 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ４選択性レセプターアゴニスト
WO2006007412A2 (fr) * 2004-06-16 2006-01-19 Nastech Pharmaceutical Company Inc. Preparations a base de peptide yy presentant une stabilite accrue et une meilleure resistance aux agents microbiens
AU2005271878B2 (en) * 2004-07-12 2010-02-18 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
KR20070039593A (ko) * 2004-07-21 2007-04-12 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
US7820676B2 (en) 2004-08-23 2010-10-26 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
PA8660701A1 (es) * 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
AU2005327332B2 (en) * 2005-02-08 2010-07-22 Woodford Associates Limited Non-alcoholic beverage enriched with 1H216O
ATE505532T1 (de) * 2005-02-08 2011-04-15 Woodford Associates Ltd Mit 1h2160 angereichertes alkoholisches getränk
KR100928384B1 (ko) * 2005-03-05 2009-11-23 세르게이 파브로비치 솔로비에프 1h216o가 강화된 화장품 조성물
EA011143B1 (ru) * 2005-03-11 2009-02-27 Вада Консалтинг Лимитед Метод стимуляции роста волос и их регенерации
EA012855B1 (ru) * 2005-03-11 2009-12-30 Вада Консалтинг Лимитед Легкая фармацевтическая вода, терапевтические композиции, ее содержащие, способы их производства и применения
CN101146448A (zh) * 2005-03-11 2008-03-19 维达咨询有限公司 用于消毒无生命表面的组合物
JP2008533005A (ja) * 2005-03-11 2008-08-21 ヴァーダ コンサルティング リミテッド 生物学的活性物質の皮内的、経皮的又は経粘膜的送達のための方法
RU2275920C1 (ru) * 2005-04-01 2006-05-10 Игорь Анатольевич Помыткин Способ лечения новообразований
CA2614619A1 (fr) * 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations permettant d'ameliorer l'administration par les muqueuses de pyy
CA2621806C (fr) 2005-09-14 2016-08-02 Mannkind Corporation Procede de preparation de medicaments fonde sur l'accroissement de l'affinite des surfaces de microparticules cristallines pour des principes actifs
EP1971350A1 (fr) * 2005-12-12 2008-09-24 VADA Consulting Limited Procede pour traiter le syndrome metabolique
US20080292718A1 (en) * 2005-12-12 2008-11-27 Igor Anatolievich Pomytkin Method for Suppression Appetite and Food Intake
CA2633180A1 (fr) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Methodes permettant de traiter l'obesite au moyen d'enterostatine
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
US20070149442A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Non-hygroscopic compositions of enterostatin
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
US8106013B2 (en) 2006-05-19 2012-01-31 Georgia Tech Research Corporation ABC transporter ligand GATX1
RU2301067C1 (ru) * 2006-06-19 2007-06-20 Сергей Павлович Соловьев Средство и способ для повышения половой активности человека
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US20080015265A1 (en) * 2006-07-11 2008-01-17 Byron Rubin Methods of treating obesity using satiety factors
EP2049138A4 (fr) 2006-07-14 2011-11-09 Georgia Tech Res Inst Ligand du canal clc
EP2046826B1 (fr) 2006-07-24 2011-09-14 Biorexis Pharmaceutical Corporation Protéines de fusion d'extendine
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
GB0708226D0 (en) * 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
WO2009002867A2 (fr) 2007-06-26 2008-12-31 Nutrition 21, Inc. Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
US8889622B2 (en) * 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
WO2009033747A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide comme agent thérapeutique
CN101939443B (zh) * 2008-02-08 2014-01-29 Ambrx公司 经修饰瘦素多肽和其用途
EP2265630B1 (fr) 2008-04-14 2014-10-29 The General Hospital Corporation Agents ciblé vers la plectine-1 de façon à détecter et traiter l'adénocarcinome du conduit pancréatique
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA3086027C (fr) 2008-06-13 2022-05-17 Mannkind Corporation Inhalateur de poudre seche et systeme d'administration de medicament
RU2470681C2 (ru) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Интерактивное устройство и способ профилирования усилий при ингаляции в реальном масштабе времени
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
WO2010068414A2 (fr) * 2008-11-25 2010-06-17 Bowen Richard L Méthodes pour traiter une maladie associée à l'obésité
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2676695A3 (fr) 2009-03-11 2017-03-01 MannKind Corporation Appareil, système et procédé de mesure de résistance d'un inhalateur
KR20210027546A (ko) 2009-06-12 2021-03-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
CN102573875A (zh) * 2009-08-14 2012-07-11 阿勒根公司 使用速激肽再靶向内肽酶治疗癌症的方法
US8207651B2 (en) 2009-09-16 2012-06-26 Tyco Healthcare Group Lp Low energy or minimum disturbance method for measuring frequency response functions of ultrasonic surgical devices in determining optimum operating point
KR101026864B1 (ko) 2009-10-08 2011-04-12 (주)송호바이오메드 고 수용성 ２―하이드록시프로필―베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물
WO2011056889A1 (fr) 2009-11-03 2011-05-12 Mannkind Corporation Appareil et méthode de simulation d'efforts d'inhalation
EP2538929A4 (fr) 2010-02-25 2014-07-09 Univ Johns Hopkins Délivrance prolongée d'agents thérapeutiques à un compartiment oculaire
JP5819949B2 (ja) 2010-06-10 2015-11-24 ミダテック リミテッド ナノ粒子フィルム送達システム
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
WO2012109363A2 (fr) 2011-02-08 2012-08-16 The Johns Hopkins University Vecteurs géniques pénétrant le mucus
EP2694402B1 (fr) 2011-04-01 2017-03-22 MannKind Corporation Emballage coque pour cartouches pharmaceutiques
RU2476227C2 (ru) * 2011-04-14 2013-02-27 Ольга Георгиевна Мельникова Способ снижения избыточного веса
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
CN104470516A (zh) 2011-12-11 2015-03-25 瑞克欧制药有限公司 鼻内右美托咪定组合物和其使用方法
CA2867203C (fr) 2012-03-16 2016-09-20 The Johns Hopkins University Conjugues copolymere multi-blocs non lineaire-medicament pour l'administration de principes actifs
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US10688041B2 (en) 2012-05-03 2020-06-23 Kala Pharmaceuticals, Inc. Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
EA034393B1 (ru) 2012-11-13 2020-02-03 Адосиа Состав инсулина быстрого действия, содержащий замещенное анионное соединение
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
US10017554B2 (en) 2013-04-10 2018-07-10 University Of Copenhagen Neuropeptide Y-derived peptides
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
WO2015021064A1 (fr) 2013-08-05 2015-02-12 Mannkind Corporation Appareil d'insufflation et procédés
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
US20170081366A1 (en) * 2015-09-22 2017-03-23 Kyungpook National University Industry - Academic Cooperation Foundation Novel Peptides for Preventing or Treating Bone Diseases and Use Thereof
WO2017083779A1 (fr) 2015-11-12 2017-05-18 Graybug Vision, Inc. Aggrégation de microparticules pour un usage thérapeutique
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
US20200062823A1 (en) * 2017-05-16 2020-02-27 The University Of Chicago Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism
CA3087733A1 (fr) 2018-01-23 2019-08-01 Gila Therapeutics, Inc. Formulations pharmaceutiques de peptide yy, compositions et procedes
WO2023046336A1 (fr) * 2021-09-22 2023-03-30 Ferring B.V. Compositions peptidique d'hormone adrénocorticotrope et méthodes d'utilisation

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
ES2097783T3 (es) * 1991-01-15 1997-04-16 Hemosphere Inc Nanomatrices proteicas y procedimiento de produccion.
US6391343B1 (en) * 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
CA2139764C (fr) * 1992-07-07 1999-02-23 Wayne N. Collette Methode de formage d'une preforme multicouche et d'un contenant muni d'une couche interieure a faibler cristallisation
DK0678018T3 (da) 1993-01-06 2003-04-28 Kinerton Ltd Ion molekylærkonjugater af bionedbrydelige polyestere og bioaktive polypeptider
EP0692971A4 (fr) 1993-03-29 1997-11-12 Univ Cincinnati Analogues du peptide yy et leurs utilisations
CZ292586B6 (cs) 1993-08-09 2003-10-15 Societe De Conseils De Recherches Et D´Application Somatostatinový nebo bombesidový derivát a jejich použití
US5696093A (en) * 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) * 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5912227A (en) * 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
CA2220451A1 (fr) * 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methodes et compositions pour ameliorer la digestion et l'absorption dans l'intestin grele
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5716643A (en) * 1995-06-07 1998-02-10 Hemosphere Inc. Large scale production of medicine coated crosslinked protein microspheres
US6017897A (en) * 1995-06-07 2000-01-25 Pasteur Merieux Connaught Canada Nucleic acid respiratory syncytial virus vaccines
FR2736265B1 (fr) * 1995-07-07 1997-09-26 Forgeot Marcel Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP1015007A1 (fr) 1996-11-13 2000-07-05 The University Of Cincinnati Analogues de peptide yy et leurs utilisations
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
WO1998055105A1 (fr) * 1997-06-05 1998-12-10 Hemosphere, Inc. Microspheres enrobees de fibrinogene
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
IT1293088B1 (it) 1997-07-10 1999-02-11 Isi Ist Sierovaccinogeno Ital Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU9185598A (en) 1997-09-25 1999-04-12 Banyu Pharmaceutical Co., Ltd. Novel neuropeptide y receptor antagonists
WO1999038535A1 (fr) 1998-01-29 1999-08-05 Kinerton Limited Procede de preparation de microparticules pouvant etre absorbees
US6046167A (en) * 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
US6017879A (en) * 1998-04-03 2000-01-25 B.M.R.A. Corporation B.V. Template associated NPY Y2-receptor agonists
DK1189629T3 (da) 1999-02-10 2011-01-03 Curis Inc Peptid YY (PYY) til behandling af glucosestofskiftesygdomme
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
ATE450269T1 (de) 2000-12-14 2009-12-15 Amylin Pharmaceuticals Inc Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE60230818D1 (de) * 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
KR20040058324A (ko) 2001-11-26 2004-07-03 다이이찌 산토리 파마 가부시키가이샤 경비흡수용 의약 조성물
EP2329839B1 (fr) 2002-01-10 2015-09-16 Imperial Innovations Limited Modification du comportement d'alimentation par GLP-1 et PYY
AU2003243545A1 (en) 2002-06-14 2003-12-31 Amylin Pharmaceuticals, Inc. Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof

Also Published As

Publication number Publication date
MXPA05006572A (es) 2005-12-14
EA008829B1 (ru) 2007-08-31
EP1581245A2 (fr) 2005-10-05
NO20053430D0 (no) 2005-07-14
US20070197437A1 (en) 2007-08-23
NO20053430L (no) 2005-09-15
WO2004056314B1 (fr) 2005-09-29
WO2004056314A3 (fr) 2005-03-31
CO5700705A2 (es) 2006-11-30
WO2004056314A2 (fr) 2004-07-08
US20040157777A1 (en) 2004-08-12
BR0316685A (pt) 2005-11-01
JP2006516262A (ja) 2006-06-29
US20070129299A1 (en) 2007-06-07
AU2003299722A1 (en) 2004-07-14
EA200501007A1 (ru) 2006-02-24
ECSP055839A (es) 2006-03-01
CA2510199A1 (fr) 2004-07-08
US7186691B2 (en) 2007-03-06
US7157426B2 (en) 2007-01-02
US20040209807A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
MA27535A1 (fr) Compositions et procedes permettant d'ameliorer l'administration aux muqueuses de peptides de liaison du recepteur y2, et procedes pour le traitement et la prevention de l'obesite
PL377443A1 (pl) Kompozycja do leczenia zmarszczek, drobnych zmarszczek i nadmiernego pocenia się oraz sposób jej zastosowania
EP1773369A4 (fr) Compositions pharmaceutiques et methodes de traitement d'un peptide
IL178038A (en) Delayed-release oral dosage forms for pain management
EP1827468A4 (fr) Acetate de leuprolide et inhibiteurs de l'acetylcholinesterase ou antagonistes des recepteurs nmda pour le traitement de la maladie d'alzheimer
GB2427708C3 (en) Projection apparatus and method for pepper's ghostillusion
WO2005102338A8 (fr) Methode de traitement de la douleur neuropathique au moyen d'un antagoniste du recepteur crth2
TWI346558B (en) Pharmaceutical composition for chronic treatment of inflammation and use thereof
FR2840804B1 (fr) Systeme pour le traitement de l'obesite et implant pour un tel systeme
PL1644021T3 (pl) Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
HK1072559A1 (en) Methods and dosage forms for controled delivery ofpaliperidone
AU2003233583A8 (en) Oral lactoferrin in the treatment of respiratory disorders
EP2783697A3 (fr) Fragments de VIP et procédés d'utilisation
WO2002053180A3 (fr) Compositions immunisantes et leurs procedes d'utilisation
EP1745793A4 (fr) Absorbant pour administration orale, agent thérapeutique ou préventif pour une maladie rénale et agent thérapeutique ou préventif pour une maladie hépatique
IL160927A0 (en) Compositions and methods for delivery of poorly water soluble drugs and method of treatment
NO20055187D0 (no) Fremgangsmate for behandling og forebygging av lavere urinkanal symptomer
EP1648417A4 (fr) Formulation pharmaceutique et procede de traitement de troubles gastro-intestinaux lies a l'acidite
MA30901B1 (fr) Therapie de combinaison sequentielle
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
GB0228305D0 (en) Therapeutic composition for respiratory delivery
WO2002083074A3 (fr) Procedes de traitement de troubles hepatiques
EP1551452A4 (fr) Compositions et procedes pour traitement therapeutique
AU2003228356A8 (en) Methods and compositions for preventing obesity and obesity related disorders
EP1551456A4 (fr) Composition pharmaceutique servant a prevenir et a traiter des maladies renales